Idexx Laboratories IDXX Proceeds from exercises of stock options and other stock issuances
Proceeds from exercises of stock options and other stock issuances at other companies
Other financials
Where this comes from
Reported directly by Idexx Laboratories in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: Idexx Laboratories’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Idexx Laboratories's proceeds from exercises of stock options and other stock issuances.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Idexx Laboratories's proceeds from exercises of stock options and other stock issuances?
- Idexx Laboratories (IDXX) reported proceeds from exercises of stock options and other stock issuances of $18.16M in Q1 2026.
- How has Idexx Laboratories's proceeds from exercises of stock options and other stock issuances changed year-over-year?
- Idexx Laboratories's proceeds from exercises of stock options and other stock issuances increased by 152.5% year-over-year, from $7.19M to $18.16M.
- What is the long-term trend for Idexx Laboratories's proceeds from exercises of stock options and other stock issuances?
- Over 4 years (2021 to 2025), Idexx Laboratories's proceeds from exercises of stock options and other stock issuances has grown at a 19.0% compound annual growth rate (CAGR), from $46.57M to $93.36M.
- What does proceeds from exercises of stock options and other stock issuances mean?
- This metric tracks the cash inflows received from employees when they exercise stock options or purchase shares through employee stock purchase plans. It represents a source of liquidity generated from equity-based compensation programs. It is a recurring item for companies with significant stock-based incentive structures.